Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA) end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
本文档由 201dc038a8 分享于2020-05-14 07:38
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA) end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
下载文档
收藏
打印
分享：
君，已阅读到文档的结尾了呢~~